Eterna Therapeutics
ERNA
18 hedge funds and large institutions have $292K invested in Eterna Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
38% more funds holding
Funds holding: 13 → 18 (+5)
0.03% less ownership
Funds ownership: 0.04% → 0.01% (-0.03%)
61% less capital invested
Capital invested by funds: $747K → $292K (-$455K)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$171K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$42K |
| 3 |
Millennium Management
New York
|
+$32.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.5K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$48.3K |
| 2 |
NW
Naviter Wealth
Little Rock,
Arkansas
|
-$22.8K |
| 3 |
SCA
Sippican Capital Advisors
Boston,
Massachusetts
|
-$13.6K |
| 4 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
-$8.97K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| – | -$5.24K | -13 | Closed |
|
|
APC
27
Aspire Private Capital
Cornelius,
North Carolina
| – | -$11 | – | – |
|
28
Morgan Stanley
New York
| – | -$53 | – | – |
|
ERNA Hedge Fund Activity: Q4 2024 in Review
18 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q4 2024, worth a combined $292K — down 61% from $747K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ERNA positions and 2 closed out — a net gain of 5 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $171K. The largest seller was UBS Group, cutting an estimated $48.3K.
- 18 institutional investors held Eterna Therapeutics (ERNA) as of Q4 2024, up from 13 in Q3 2024.
- Funds reported $292K of Eterna Therapeutics stock for Q4 2024, down 61% quarter-over-quarter.
- 7 funds opened new Eterna Therapeutics positions in Q4 2024 and 2 closed out, a net change of +5 holders.
- The largest Eterna Therapeutics buyer in Q4 2024 was Geode Capital Management, an estimated $171K added.
- The largest Eterna Therapeutics seller in Q4 2024 was UBS Group, an estimated $48.3K sold.
Based on aggregated 13F filings for Q4 2024.